N-(1-(cyclopropylmethyl)pyrrolidin-3-yl)-5-((2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl)-2-fluorobenzamide

ID: ALA4533690

PubChem CID: 141726120

Max Phase: Preclinical

Molecular Formula: C24H25FN4O3

Molecular Weight: 436.49

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  O=C(NC1CCN(CC2CC2)C1)c1cc(Cn2c(=O)[nH]c(=O)c3ccccc32)ccc1F

Standard InChI:  InChI=1S/C24H25FN4O3/c25-20-8-7-16(13-29-21-4-2-1-3-18(21)22(30)27-24(29)32)11-19(20)23(31)26-17-9-10-28(14-17)12-15-5-6-15/h1-4,7-8,11,15,17H,5-6,9-10,12-14H2,(H,26,31)(H,27,30,32)

Standard InChI Key:  ZKLQWWOVTJLLRS-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 32 36  0  0  0  0  0  0  0  0999 V2000
   15.9710  -25.7291    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.9698  -26.5486    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.6779  -26.9576    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.6761  -25.3202    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.3847  -25.7255    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.3835  -26.5461    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.0897  -26.9552    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.8016  -26.5481    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.8028  -25.7275    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.0920  -25.3139    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.0921  -24.4967    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   18.0874  -27.7724    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.7940  -28.1830    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.7904  -28.9990    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.4961  -29.4095    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.2059  -29.0028    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.2056  -28.1814    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.4993  -27.7746    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.9130  -29.4124    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   20.9130  -27.7723    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.9124  -26.9551    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   19.5082  -26.9587    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   21.6223  -28.1765    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   22.3277  -27.7636    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1011  -28.0151    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.5817  -27.3542    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   23.1016  -26.6929    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.3244  -26.9452    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.3989  -27.3546    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.8072  -28.0624    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.8081  -28.8771    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.5160  -28.4688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  6  2  0
  5  4  2  0
  4  1  1  0
  5  6  1  0
  5 10  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
  7 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 13  1  0
 16 19  1  0
 17 20  1  0
 20 23  1  0
 20 21  2  0
  8 22  2  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 28 24  1  0
 26 29  1  0
 29 30  1  0
 31 30  1  0
 32 31  1  0
 30 32  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4533690

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 436.49

Molecular Weight (Monoisotopic): 436.1911

AlogP: 2.09

#Rotatable Bonds: 6

Polar Surface Area: 87.20

Molecular Species: BASE

HBA: 5

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 9.65

CX Basic pKa: 8.54

CX LogP: 2.07

CX LogD: 1.09

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.62

Np Likeness Score: -1.89

References

1. Jain PG, Patel BD..  (2019)  Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.,  165  [PMID:30684797] [10.1016/j.ejmech.2019.01.024]

2. Liu T, Song S, Wang X, Hao J..  (2021)  Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer.,  210  [PMID:33158576] [10.1016/j.ejmech.2020.112954]

3. Bansal R, Malhotra A..  (2021)  Therapeutic progression of quinazolines as targeted chemotherapeutic agents.,  211  [PMID:33243532] [10.1016/j.ejmech.2020.113016]

4. Zhang J, Gao Y, Zhang Z, Zhao J, Jia W, Xia C, Wang F, Liu T..  (2022)  Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment.,  65  (24.0): [PMID:36512711] [10.1021/acs.jmedchem.2c01352]

Source

Source(1):

• Scientific Literature